Potential prognostic value of miR-132 and miR-212 expression in mCRPC patients
DOI:
https://doi.org/10.4081/aiua.2021.3.373Keywords:
Letter to the editorAbstract
To the Editor,
we have been very pleased to read the interesting work proposed by Salemi et al. regarding the expression of specific fragments of microRNA (miRNA), particularly miR-132 and miR-212, as potential key regulators in prostate cancer (PCa). As outlined by the Authors, the altered expression of miRNAs in cancer pathogenesis represents a well-consolidated knowledge in the current literature. More specifically, both miR-212 and miR-132 regulate subsets of genes involved in tumor progression in several tumor cell types as PCa, proving a central role in tumorigenesis, cell adhesion, and angiogenesis. In addition, a strong association between miR-132 expression and high Gleason score PCa has been lately depicted [...].
Downloads
References
Salemi M, Pettinato A, Fraggetta F, et al. Expression of miR-132 and miR-212 in prostate cancer and metastatic lymph node: Case report and revision of the literature. Arch Ital Urol Androl. 2020; 92:209-210. DOI: https://doi.org/10.4081/aiua.2020.3.209
Hassan O, Ahmad A, Sethi S, and Sarkar FH. Recent updates on the role of microRNAs in prostate cancer. J Hematol Oncol. 2012; 5:9. DOI: https://doi.org/10.1186/1756-8722-5-9
Zhang W, Edwards A, Fan W, et al. miRNA-mRNA correlation-network modules in human prostate cancer and the differences between primary and metastatic tumor subtypes. PLoS One. 2012; 7:e40130. DOI: https://doi.org/10.1371/journal.pone.0040130
Chen ZH, Zhang GL, Li HR, et al. A panel of five circulating microRNAs as potential biomarkers for prostate cancer. Prostate. 2012; 72:1443-52. DOI: https://doi.org/10.1002/pros.22495
Frantellizzi V, Monari F, Mascia M, et al. Radium-223 in mCPRC patients: a large real-life Italian multicenter study. Minerva Urol Nefrol 2020. doi: 10.23736/S0393-2249.20.03808-4. Epub ahead of print.
Frantellizzi V, Lazri J, Pontico M, et al. Bone pain palliation outcomes and possibility of Radium-223 re-treatment in mCRPC. Arch Ital Urol Androl. 2020; 92:196-199 DOI: https://doi.org/10.4081/aiua.2020.3.196
De Vincentis G, Follacchio GA, Frantellizzi V, et al. 223Ra-dichloride therapy in an elderly bone metastatic castration-resistant prostate cancer patient: a case report presentation and comparison with existing literature. Aging Clinical and Experimental Research. 2017; 30:677-80. DOI: https://doi.org/10.1007/s40520-017-0826-4
Ricci M, Frantellizzi V, Bulzonetti N, De Vincentis G. Reversibility of castration resistance status after Radium-223 dichloride treatment: clinical evidence and review of the literature. Int J Radiat Biol. 2019; 95:554-561. DOI: https://doi.org/10.1080/09553002.2019.1558301
Frantellizzi V, Costa R, Mascia M, et al. Primary radical prostatectomy or ablative radiotherapy as protective factors for patients with mCRPC treated with radium-223 dichloride: an Italian multicenter study. Clin Genitourin Cancer. 2020; 18:185-91. DOI: https://doi.org/10.1016/j.clgc.2019.10.009
De Vincentis G, Follacchio GA, Frantellizzi V, et al. Prostate-specific antigen flare phenomenon during 223Ra-dichloride treatment for bone metastatic castration-resistant prostate cancer: a case report. Clinical Genitourinary Cancer. 2016; 14:e529-e33. DOI: https://doi.org/10.1016/j.clgc.2016.04.014
Prelaj A, Rebuzzi SE, Buzzacchino F, et al. Radium-223 in patients with metastatic castration-resistant prostate cancer: Efficacy and safety in clinical practice. Oncol Lett. 2019; 17:1467-76. DOI: https://doi.org/10.3892/ol.2018.9785
Abuodeh Y, Venkat P, Kim S. Systematic review of case reports on the abscopal effect. Curr Probl Cancer. 2016; 40:25-37. DOI: https://doi.org/10.1016/j.currproblcancer.2015.10.001
Yilmaz MT, Elmali A, Yazici G. Abscopal Effect, From Myth to Reality: From Radiation Oncologists' Perspective. Cureus. 2019;11:e3860. DOI: https://doi.org/10.7759/cureus.3860
Downloads
Published
Issue
Section
License
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
